CO2-equiv emissions: 6.93M tons (7.63M); 74.6 tons/1M pounds sterling of sales (79.2)
Water Intake/Use: Use: 18.7M cubic meters (19.2M); 692 cubic meters/1M pounds sterling of sales (704)
Hazardous Waste: 191.5 kilotons (214.5k)
Nonhazardous waste: 169.5k tons (171.8k)
Energy: 24.3M gigajoules (26M); 903 gigajoules/ £1M (955)
Among GlaxoSmithKline's most highly visible sustainability accomplishments is the 11,000-panel solar array at a regional distribution center in York, PA. The solar setup provides all of the facility's power and saves 1,800 tons of CO2 per year, the company says. GSK also has raised wind turbines at its Barnard Castle site.
And in Philadelphia, the big pharma expects by 2013 to go Platinum--the highest rating in the Leadership in Energy & Environmental Design sustainable building rating system--in a four-story building. It's being architected by GSK and designers who've been imagining how employees will use the workspace of the future.
In addition, GSK is targeting sustainability in manufacturing processes. It has teamed with Singapore on resource efficiency and waste minimization in drug-making. Among projects under way are research into chemical-, physical- and bio-transformations. The initiative is funded by a $35 million pot established by the collaborators. GSK's interest in manufacturing enhancements complements Singapore's goal of becoming a green and sustainable manufacturing hub.
GSK also appears to be linking its sustainability investments with process analytical technology initiatives. In a survey by PharmaManufacturing.com, 10 percent of respondents say sustainability has become a key driver of their PAT efforts. About half of the respondents say they see PAT as a means toward sustainability and green practices.